GlassScriptPhysician profile
Robert C Bransfield
NPI 1467449769
$414,750.70
in general payments reported to CMS, 2019-2025
38 companies · $113K in 2025
The $113K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,072 · 2020: $4,543 · 2021: $18K · 2022: $85K · 2023: $80K · 2024: $114K · 2025: $113K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $245K · Travel and Lodging: $34K · Food and Beverage: $15K · Consulting Fee: $12K · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $244,910.63 |
| Travel and Lodging | $34,448.20 |
| Food and Beverage | $14,607.13 |
| Consulting Fee | $12,000.00 |
| Education | $151.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $375,691.37 | 2020-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $17,455.59 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $7,822.46 | 2022-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $2,645.63 | 2024 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $1,586.93 | 2019-2022 | |
| Abbvie INC. | $1,511.91 | 2021-2025 | Vraylar |
| Jazz Pharmaceuticals INC. | $1,180.96 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $899.69 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $790.40 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $588.01 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Mycite |
| Validus Pharmaceuticals LLC | $551.97 | 2020-2024 | Equetro |
| Bausch Health US, LLC | $420.39 | 2019-2025 | Aplenzin, Wellbutrin |
| Alkermes, INC. | $373.81 | 2021-2025 | Aristada, Lybalvi |
| Tris Pharma INC | $338.37 | 2022-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $301.55 | 2023-2025 | Sunosi, Auvelity |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $290.75 | 2019-2025 | Fanapt, Hetlioz |
| Corium, LLC | $284.21 | 2022-2025 | Azstarys, Adlarity |
| Rhodes Pharmaceuticals L.P. | $262.39 | 2019 | |
| Almatica Pharma LLC | $259.33 | 2021-2025 | Loreev Xr |
| Lundbeck LLC | $211.45 | 2019-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $171.83 | 2021-2023 | Belsomra |
| Neurocrine Biosciences, INC. | $169.09 | 2020-2024 | Ingrezza |
| Biohaven Pharmaceuticals, INC. | $142.69 | 2021 | |
| Harmony Biosciences LLC | $142.67 | 2020-2025 | Wakix |
| Janssen Pharmaceuticals, INC | $109.98 | 2021-2023 | Spravato |
| Neos Therapeutics, LP | $103.48 | 2019-2022 | |
| Noven Therapeutics, LLC | $99.30 | 2020-2024 | Xelstrym |
| Eisai INC. | $79.12 | 2020-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $62.31 | 2023-2024 | Lumryz |
| Arbor Pharmaceuticals, INC. | $40.69 | 2022 | |
| Adlon Therapeutics L.P. | $37.84 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $30.33 | 2024 | |
| Shire North American Group INC | $23.38 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.19 | 2023 | Horizant |
| Collegium Pharmaceutical, INC. | $15.22 | 2025 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $14.03 | 2023 | Subvenite, Lamotrigine |
| Avanir Pharmaceuticals, INC. | $13.69 | 2019 | |
| Aytu Biopharma, INC. | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bransfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.